RxDoctor Payments Data

Shannon St Clair, MD

Nuclear Cardiology · Winston Salem, NCNPI 1003073396

Payments from drug & device makers

$1,325in general payments, 2019–2025

Across 63 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$317
  • Amgen$157
  • Philips North America LLC$149
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$130
  • Novo Nordisk$126
  • Abbott$121
  • plus $325 from 7 others

What the payments were for

  • Food & beverage$1,325100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few nuclear cardiology providers in North Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$97,878
Medicare patients
1,027
Services billed
2,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab469$302,002
EliquisApixaban257$289,251
EntrestoSacubitril/Valsartan146$161,546
XareltoRivaroxaban69$77,085
Praluent PenAlirocumab91$43,884
JardianceEmpagliflozin46$42,712
FarxigaDapagliflozin Propanediol36$28,204
BrilintaTicagrelor14$16,325
VascepaIcosapent Ethyl14$8,210
Metoprolol Succinate568$7,494
NexletolBempedoic Acid15$6,079
Atorvastatin Calcium350$3,664
Ranolazine ErRanolazine32$2,744
Ezetimibe166$2,358
Rosuvastatin Calcium263$2,263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$51$289,251257 claims
NovartisEntresto$317$161,546146 claims
AstraZenecaFarxiga, Brilinta$17$44,52950 claims
Boehringer IngelheimJardiance$102$42,71246 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few nuclear cardiology providers in North Carolinaon file to place this against a meaningful peer group, so we don't.

Other nuclear cardiology in Winston Salem

Where these figures come from

Is this you, or does something look wrong? →